Cyclic Prosaposins Peptides and Uses Thereof - Cancer Treatment

USPTO published patent application US20260091083A1 filed by Children's Medical Center Corporation for cyclic prosaposin peptides used in cancer treatment and inflammatory diseases. The application (No. 19186486) was filed on April 22, 2025, and published April 2, 2026, naming Randolph S. Watnick as inventor.

Saposin-A Derived Peptides with Anti-Angiogenic Activity for Tumor Treatment

The USPTO published patent application US20260091079A1 by Children's Medical Center Corporation covering Saposin-A derived polypeptides with anti-angiogenic activity. The peptides consist of 9 or fewer amino acid residues containing the active core sequence DWLP. The disclosed invention can be used to inhibit tumor growth and cancer metastasis.

Oligopeptide Inhibits Angiogenesis and Vascular Function

The USPTO published patent application US20260091078A1 covering an oligopeptide composition of 3-7 amino acids that inhibits angiogenesis and vascular function. The oligopeptide comprises defined sequence patterns with basic, small, polar, and hydrophobic amino acid residues. The application claims priority from July 7, 2020.

Fc-IL2 variant cancer therapy combination patents

USPTO published patent application US20260091062A1 by Hoffmann-La Roche Inc. covering recombinant Fc domain-IL-2 variant polypeptides combined with membrane-anchored antigen binding polypeptides for cancer treatment. The application (No. 19272092) was filed July 17, 2025, and published April 2, 2026.

Anti-GCC Antibodies and CARs for Immunotherapy

USPTO published patent application US20260091061A1 disclosing anti-GCC single domain antibodies and chimeric antigen receptors (CARs) for cancer immunotherapy. The application, filed September 28, 2023, names Xiaohu Fan, Panglian Xu, Qiuchuan Zhuang, Min Wei, Jiangjing Tang, Chenchen Zheng, and Xu Fang as inventors. This publication does not create any immediate regulatory obligations.

Antigen Receptors and Uses Thereof

USPTO published patent application US20260091060A1 by Holger Voss et al. covering recombinant antigen receptors and engineered T cells for disease treatment. The application (No. 18905085) was filed October 2, 2024 and published April 2, 2026. The invention relates to treating diseases by targeting cells expressing specific antigens using engineered T cell therapy.

Coronavirus Vaccine Nucleic Acid LNP Patent

USPTO published CureVac SE's patent application (US20260091107A1) for nucleic acid sequences and compositions suitable for coronavirus vaccines, particularly COVID-19, delivered via lipid nanoparticle (LNP) technology. The application covers compositions, vaccines, first and second medical uses, and methods of treatment or prevention. Filed as Application No. 19317057 with priority date September 2, 2025.

Macrophage targeting drug conjugates with mannose linker

The USPTO published patent application US20260091117A1 for macrophage targeting drug conjugates developed by P.I.F. Entrepreneurs Ltd. The conjugates comprise a drug moiety, mannose moiety, and linker (hydrazone or oxime group) for targeted therapeutic delivery. Application No. 19411275 was filed December 7, 2025.

BacPROTACs for Targeted Protein Degradation in Bacteria

Washington University published patent application US20260091118A1 for bivalent agents (BacPROTACs) designed for targeted protein degradation in mycobacteria and other bacteria, including methods for reducing antibiotic resistance. The application (No. 19312129, filed August 27, 2025) covers compositions and methods for treating antibiotic-resistant bacterial infections.

Targeted Delivery System Using CD45+ Leukocyte Cells for Glioma Treatment

USPTO published patent application US20260091119A1 disclosing an isolated targeted delivery system using CD45+ leukocyte cells containing iron binding proteins complexed with therapeutic or diagnostic agents for glioma treatment. Inventors include Magdalena KRÓL and seven co-inventors. The application was filed on September 1, 2023.